Strategies for implementation of a multidisciplinary approach to the treatment of nosocomial infections in critically ill patients

References

• Martin-Loeches I, Deja M, Koulenti D, et al. Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med. 2013;39(4):672–681.
   PubMed Web of Science ®Google Scholar
• Cantón R, Bryan J. Global antimicrobial resistance: from surveillance to stewardship. Part 1: surveillance and risk factors for resistance. Expert Rev Anti Infect Ther. 2012;10(11):1269–1271.
   PubMed Web of Science ®Google Scholar
• Zaragoza R, Vidal-Cortés P, Aguilar G, et al. Update of the treatment of nosocomial pneumonia in the ICU. Crit Care. 2020;24(1):383.
   PubMed Web of Science ®Google Scholar
• Vallecoccia MS, Dominedò C, Cutuli SL, et al. Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia? Eur Respir Rev. 2020;29:157.
   Web of Science ®Google Scholar
• Saied W, Martin-Loeches I, Timsit JF. What is new in non-ventilated ICU-acquired pneumonia? Intensive Care Med. 2020;46(3):488–491.
   PubMed Web of Science ®Google Scholar
• Metersky ML, Wang Y, Klompas M, et al. Trend in ventilator-associated pneumonia rates between 2005 and 2013. Jama. 2016;316(22):2427–2429.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. Jama. 2009;302(21):2323–2329.
   PubMed Web of Science ®Google Scholar
• Bitterman R, Hussein K, Leibovici L, et al. Systematic review of antibiotic consumption in acute care hospitals. Clin Microbiol Infect. 2016;22(6):561.e567-561.e519.
   PubMed Web of Science ®Google Scholar
• Hood G, Hand KS, Cramp E, et al. Measuring appropriate antibiotic prescribing in acute hospitals: development of a national audit tool through a delphi consensus. Antibiotics (Basel). 2019;8:2.
   Web of Science ®Google Scholar
• Martín-Loeches I, Diaz E, Vallés J. Risks for multidrug-resistant pathogens in the ICU. Curr Opin Crit Care. 2014;20(5):516–524.
   PubMed Web of Science ®Google Scholar
• Davey P, Marwick CA, Scott CL, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017;2(2):Cd003543.
   PubMedGoogle Scholar
• Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European respiratory society (ers), european society of intensive care medicine (ESICM), European society of clinical microbiology and infectious diseases (ESCMID) and asociación latinoamericana del tórax (ALAT). Eur Respir J. 2017;50:3.
   Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis. 2016;63(5):e61–e111.
   PubMed Web of Science ®Google Scholar
• Hawkey PM, Warren RE, Livermore DM, et al. Treatment of infections caused by multidrug-resistant gram-negative bacteria: report of the british society for antimicrobial chemotherapy/healthcare infection society/British infection association joint working party. J Antimicrob Chemother. 2018;73(suppl_3):iii2–iii78.
   PubMedGoogle Scholar
• Tacconelli E, Sifakis F, Harbarth S, et al. Surveillance for control of antimicrobial resistance. 2018 Mar;18(3):e99–e106. 10.1016/S1473-3099(17)30485-1. Epub 2017 Nov 5.
   Google Scholar
• Kelly DN, Martin-Loeches I. Comparing current US and European guidelines for nosocomial pneumonia. Curr Opin Pulm Med. 2019;25(3):263–270.
   PubMed Web of Science ®Google Scholar
• Namias N, Samiian L, Nino D, et al. Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies. J Trauma. 2000;49(4):638–645. discussion 645–636
   PubMedGoogle Scholar
• Depuydt PO, Blot SI, Benoit DD, et al. Antimicrobial resistance in nosocomial bloodstream infection associated with pneumonia and the value of systematic surveillance cultures in an adult intensive care unit. Crit Care Med. 2006;34(3):653–659.
   PubMed Web of Science ®Google Scholar
• De Bus L, Gadeyne B, Steen J, et al. A complete and multifaceted overview of antibiotic use and infection diagnosis in the intensive care unit: results from a prospective four-year registration. Crit Care. 2018;22(1):241.
   PubMedGoogle Scholar
• Meyer E, Lapatschek M, Bechtold A, et al. Impact of restriction of third generation cephalosporins on the burden of third generation cephalosporin resistant K. pneumoniae and E. coli in an ICU. Intensive Care Med. 2009;35(5):862–870.
   PubMed Web of Science ®Google Scholar
• Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of america and the society for healthcare epidemiology of America. Clin Infect Dis. 2016;62(10):e51–77.
   PubMed Web of Science ®Google Scholar
• Gackowska A, Studziński W, Kudlek E, et al. Estimation of physicochemical properties of 2-ethylhexyl-4-methoxycinnamate (EHMC) degradation products and their toxicological evaluation. Environ Sci Pollut Res Int. 2018;25(16):16037–16049.
   PubMed Web of Science ®Google Scholar
• Sleep D. Albumin and its application in drug delivery. Expert Opin Drug Deliv. 2015;12(5):793–812.
   PubMed Web of Science ®Google Scholar
• Ulldemolins M, Soy D, Llaurado-Serra M, et al. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. Antimicrob Agents Chemother. 2015;59(9):5520–5528.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498–509.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Nováček M, Ü K, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19(12):1299–1311.
   PubMed Web of Science ®Google Scholar
• Udy AA, Varghese JM, Altukroni M, et al. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012;142(1):30–39.
   PubMed Web of Science ®Google Scholar
• Hobbs AL, Shea KM, Roberts KM, et al. Implications of augmented renal clearance on drug dosing in critically Ill patients: a focus on antibiotics. Pharmacotherapy. 2015;35(11):1063–1075.
   PubMed Web of Science ®Google Scholar
• Li J, Lovern M, Riccobene T, et al. Considerations in the selection of renal dosage adjustments for patients with serious infections and lessons learned from the development of ceftazidime-avibactam. Antimicrob Agents Chemother. 2020;64(4):4.
   Web of Science ®Google Scholar
• De Waele JJ, Lipman J, Akova M, et al. Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients. Intensive Care Med. 2014;40(9):1340–1351.
   PubMed Web of Science ®Google Scholar
• McNabb JJ, Nightingale CH, Quintiliani R, et al. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy. 2001;21(5):549–555.
   PubMed Web of Science ®Google Scholar
• Cataldo MA, Tacconelli E, Grilli E, et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(1):17–24.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072–1083.
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al. Beta-lactam infusion in severe sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016;42(10):1535–1545.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Tansarli GS, Ikawa K, et al. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013;56(2):272–282.
   PubMed Web of Science ®Google Scholar
• Kasiakou SK, Sermaides GJ, Michalopoulos A, et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis. 2005;5(9):581–589.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Putcha N, Suh YD, et al. Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized controlled trials. BMC Infect Dis. 2011;11(1):181.
   Google Scholar
• Roberts JA, Abdul-Aziz MH, Davis JS, et al. Continuous versus intermittent β-lactam infusion in severe sepsis. a meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194(6):681–691.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Voulgaris GL, Maliaros A, et al. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis. 2018;18(1):108–120.
   PubMed Web of Science ®Google Scholar
• Lipman J, Brett SJ, De Waele JJ. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent beta-lactam antibiotic infusion in critically ill patients with sepsis: BLING III. Crit Care Resusc. 2019 Mar;21(1):63-68.
   Google Scholar
• Chen W, Liu H, Wang Q, et al. Estimation of the area under concentration-time curve of polymyxin B based on limited sampling concentrations in Chinese patients with severe pneumonia. Eur J Clin Pharmacol. 2020; DOI:10.1007/s00228-020-02986-x
   Web of Science ®Google Scholar
• Wong G, Brinkman A, Benefield RJ, et al. An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother. 2014;69(5):1416–1423.
   PubMed Web of Science ®Google Scholar
• De Waele JJ, Carrette S, Carlier M, et al. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med. 2014;40(3):380–387.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med. 2014;40(1):32–40.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Mueller B. Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes. Intensive Care Med. 2014;40(1):141.
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Bos LD, Povoa P, et al. Tumor necrosis factor receptor 1 (TNFRI) for ventilator-associated pneumonia diagnosis by cytokine multiplex analysis. Intensive Care Med Exp. 2015;3(1):26.
   PubMedGoogle Scholar
• de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819–827.
   PubMed Web of Science ®Google Scholar
• van der Does Y, Limper M, Jie KE, et al. Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: a multicentre non-inferiority randomized clinical trial (HiTEMP study. Clin Microbiol Infect. 2018;24(12):1282–1289.
   PubMed Web of Science ®Google Scholar
• Huang DT, Yealy DM, Angus DC. Longer-term outcomes of the proact trial. N Engl J Med. 2020;382(5):485–486.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95–107.
   PubMed Web of Science ®Google Scholar
• Pepper DJ, Sun J, Rhee C, et al. Procalcitonin-guided antibiotic discontinuation and mortality in critically ill adults: a systematic review and meta-analysis. Chest. 2019;155(6):1109–1118.
   PubMed Web of Science ®Google Scholar
• Alessandri F, Pugliese F, Angeletti S, et al. Procalcitonin in the assessment of ventilator associated pneumonia: a systematic review. Adv Exp Med Biol. 2020 Oct 9;DOI: 10.1007/5584_2020_591. Online ahead of print.
   PubMedGoogle Scholar
• Kalil AC, Lisboa T. To procalcitonin, or not to procalcitonin? Chest. 2019;155(6):1085–1087.
   PubMed Web of Science ®Google Scholar
• Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388–416.
   PubMed Web of Science ®Google Scholar
• Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. Jama. 2003;290(19):2588–2598.
   PubMed Web of Science ®Google Scholar
• Pugh R, Grant C, Cooke RP, et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev. 2015;2015(8):Cd007577.
   Google Scholar
• Jc Pps M, Paciel D, Pontet J, et al. Antibiotic treatment for the ventilator‐associated pneumonia: 8 vs. 12 days randomized trial preliminary data. Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. 2007., (2007).
   Google Scholar
• da Silveira F, Nedel WL, Cassol R, et al. Acinetobacter etiology respiratory tract infections associated with mechanical ventilation: what impacts on the prognosis? A retrospective cohort study. J Crit Care. 2019;49:124–128.
   PubMed Web of Science ®Google Scholar
• Doernberg SB, Chambers HF. Antimicrobial stewardship approaches in the intensive care unit. Infect Dis Clin North Am. 2017;31(3):513–534.
   PubMed Web of Science ®Google Scholar
• Kaki R, Elligsen M, Walker S, et al. Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother. 2011;66(6):1223–1230.
   PubMed Web of Science ®Google Scholar
• Lindsay PJ, Rohailla S, Taggart LR, et al. Antimicrobial stewardship and intensive care unit mortality: a systematic review. Clin Infect Dis. 2019;68(5):748–756.
   PubMed Web of Science ®Google Scholar
• Luyt CE, Bréchot N, Trouillet JL, et al. Antibiotic stewardship in the intensive care unit. Crit Care. 2014;18(5):480.
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Lisboa T, Blot S, et al. Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med. 2009;35(3):430–438.
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Torres A, Povoa P, et al. The association of cardiovascular failure with treatment for ventilator-associated lower respiratory tract infection. Intensive Care Med. 2019;45(12):1753–1762.
   PubMed Web of Science ®Google Scholar
• Núñez-Núñez M, Navarro MD, Palomo V, et al. The methodology of surveillance for antimicrobial resistance and healthcare-associated infections in Europe (SUSPIRE): a systematic review of publicly available information. Clin Microbiol Infect. 2018;24(2):105–109.
   PubMed Web of Science ®Google Scholar
• Babu Rajendran N, Mutters NT, Marasca G, et al. Mandatory surveillance and outbreaks reporting of the WHO priority pathogens for research & discovery of new antibiotics in European countries. Clin Microbiol Infect. 2020 Jul;26(7):943.e1-943.e6;
   PubMed Web of Science ®Google Scholar
• Andremont O, Armand-Lefevre L, Dupuis C, et al. Semi-quantitative cultures of throat and rectal swabs are efficient tests to predict ESBL-Enterobacterales ventilator-associated pneumonia in mechanically ventilated ESBL carriers. Intensive Care Med. 2020;46(6):1232–1242.
   PubMed Web of Science ®Google Scholar
• Elsa M, Matthieu LD, De Ponfilly Gauthier P et al. Impact of systematic screening for AmpC-hyperproducing enterobacterales intestinal carriage in intensive care unit patients. Ann Intensive Care. 2020;10(1):149.
   PubMed Web of Science ®Google Scholar
• Timsit JF, Schwebel C, Styfalova L, et al. Impact of bronchial colonization with candida spp. on the risk of bacterial ventilator-associated pneumonia in the ICU: the FUNGIBACT prospective cohort study. Intensive Care Med. 2019;45(6):834–843.
   PubMed Web of Science ®Google Scholar
• Huang D, Qi M, Hu Y, et al. The impact of candida spp airway colonization on clinical outcomes in patients with ventilator-associated pneumonia: A systematic review and meta-analysis. Am J Infect Control. 2020;48(6):695–701.
   PubMed Web of Science ®Google Scholar